APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroblastoma Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Neuroblastoma Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025196 pages

Choose your research edition.

Industry ResearchNeuroblastoma Treatment Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroblastoma Treatment Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Neuroblastoma Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroblastoma Treatment Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroblastoma Treatment Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Neuroblastoma Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Neuroblastoma Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuroblastoma Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroblastoma Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Neuroblastoma Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neuroblastoma Treatment include Adaptimmune, CureSearch, Juno Therapeutics, Kite Pharma, NANT, Seattle Children’s, Texas Children’s, Fosun Pharmaceutical and Jiangsu Hengrui Medicine Co.,Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Neuroblastoma Treatment market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuroblastoma Treatment and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuroblastoma Treatment revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Neuroblastoma Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuroblastoma Treatment Segment by Company

Adaptimmune

CureSearch

Juno Therapeutics

Kite Pharma

NANT

Seattle Children’s

Texas Children’s

Fosun Pharmaceutical

Jiangsu Hengrui Medicine Co.,Ltd.

Novartis

Sino Biopharmaceutical

Neuroblastoma Treatment Segment by Type

Vaccine Therapy

Oncolytic Virus Therapy

Chimeric Antigen Receptor T-Cell Immunotherapy

Combination Chemotherapy

Monoclonal Antibody Therapy

Neuroblastoma Treatment Segment by Application

Hospitals

Clinics

Others

Neuroblastoma Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroblastoma Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroblastoma Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroblastoma Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Neuroblastoma Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuroblastoma Treatment industry.

Chapter 3: Detailed analysis of Neuroblastoma Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuroblastoma Treatmentrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neuroblastoma Treatment Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Vaccine Therapy Table 3. Key Players of Oncolytic Virus Therapy Table 4. Key Players of Chimeric Antigen Receptor T-Cell Immunotherapy Table 3. Key Players of Combination Chemotherapy Table 4. Key Players of Monoclonal Antibody Therapy Table 5. Global Neuroblastoma Treatment Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Hospitals Table 7. Key Players of Clinics Table 8. Key Players of Others Table 9. Global Neuroblastoma Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Neuroblastoma Treatment Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Neuroblastoma Treatment Market Share by Region (2021-2026) Table 12. Global Neuroblastoma Treatment Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Neuroblastoma Treatment Market Share by Region (2027-2032) Table 14. Neuroblastoma Treatment Industry Trends Table 15. Neuroblastoma Treatment Industry Drivers Table 16. Neuroblastoma Treatment Industry Opportunities and Challenges Table 17. Neuroblastoma Treatment Industry Restraints Table 18. Global Neuroblastoma Treatment Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Neuroblastoma Treatment Revenue Market Share by Company (2021-2026) Table 20. Global Neuroblastoma Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Neuroblastoma Treatment Key Company Head Office and Area Served Table 22. Global Neuroblastoma Treatment Company, Product Type & Application Table 23. Global Neuroblastoma Treatment Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Neuroblastoma Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Neuroblastoma Treatment Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Neuroblastoma Treatment Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Neuroblastoma Treatment Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Neuroblastoma Treatment Revenue Market Share by Type (2021-2026) Table 30. Global Neuroblastoma Treatment Revenue Market Share by Type (2027-2032) Table 31. Global Neuroblastoma Treatment Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Neuroblastoma Treatment Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Neuroblastoma Treatment Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Neuroblastoma Treatment Revenue Market Share by Application (2021-2026) Table 35. Global Neuroblastoma Treatment Revenue Market Share by Application (2027-2032) Table 36. Adaptimmune Company Information Table 37. Adaptimmune Business Overview Table 38. Adaptimmune Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Adaptimmune Neuroblastoma Treatment Product Portfolio Table 40. Adaptimmune Recent Development Table 41. CureSearch Company Information Table 42. CureSearch Business Overview Table 43. CureSearch Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. CureSearch Neuroblastoma Treatment Product Portfolio Table 45. CureSearch Recent Development Table 46. Juno Therapeutics Company Information Table 47. Juno Therapeutics Business Overview Table 48. Juno Therapeutics Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Juno Therapeutics Neuroblastoma Treatment Product Portfolio Table 50. Juno Therapeutics Recent Development Table 51. Kite Pharma Company Information Table 52. Kite Pharma Business Overview Table 53. Kite Pharma Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Kite Pharma Neuroblastoma Treatment Product Portfolio Table 55. Kite Pharma Recent Development Table 56. NANT Company Information Table 57. NANT Business Overview Table 58. NANT Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. NANT Neuroblastoma Treatment Product Portfolio Table 60. NANT Recent Development Table 61. Seattle Children’s Company Information Table 62. Seattle Children’s Business Overview Table 63. Seattle Children’s Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Seattle Children’s Neuroblastoma Treatment Product Portfolio Table 65. Seattle Children’s Recent Development Table 66. Texas Children’s Company Information Table 67. Texas Children’s Business Overview Table 68. Texas Children’s Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Texas Children’s Neuroblastoma Treatment Product Portfolio Table 70. Texas Children’s Recent Development Table 71. Fosun Pharmaceutical Company Information Table 72. Fosun Pharmaceutical Business Overview Table 73. Fosun Pharmaceutical Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Fosun Pharmaceutical Neuroblastoma Treatment Product Portfolio Table 75. Fosun Pharmaceutical Recent Development Table 76. Jiangsu Hengrui Medicine Co.,Ltd. Company Information Table 77. Jiangsu Hengrui Medicine Co.,Ltd. Business Overview Table 78. Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Product Portfolio Table 80. Jiangsu Hengrui Medicine Co.,Ltd. Recent Development Table 81. Novartis Company Information Table 82. Novartis Business Overview Table 83. Novartis Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Novartis Neuroblastoma Treatment Product Portfolio Table 85. Novartis Recent Development Table 86. Sino Biopharmaceutical Company Information Table 87. Sino Biopharmaceutical Business Overview Table 88. Sino Biopharmaceutical Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Sino Biopharmaceutical Neuroblastoma Treatment Product Portfolio Table 90. Sino Biopharmaceutical Recent Development Table 91. North America Neuroblastoma Treatment Market Size by Type (2021-2026) & (US$ Million) Table 92. North America Neuroblastoma Treatment Market Size by Type (2027-2032) & (US$ Million) Table 93. North America Neuroblastoma Treatment Market Size by Application (2021-2026) & (US$ Million) Table 94. North America Neuroblastoma Treatment Market Size by Application (2027-2032) & (US$ Million) Table 95. North America Neuroblastoma Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. North America Neuroblastoma Treatment Market Size by Country (2021-2026) Table 97. North America Neuroblastoma Treatment Market Size by Country (2027-2032) Table 98. Europe Neuroblastoma Treatment Market Size by Type (2021-2026) & (US$ Million) Table 99. Europe Neuroblastoma Treatment Market Size by Type (2027-2032) & (US$ Million) Table 100. Europe Neuroblastoma Treatment Market Size by Application (2021-2026) & (US$ Million) Table 101. Europe Neuroblastoma Treatment Market Size by Application (2027-2032) & (US$ Million) Table 102. Europe Neuroblastoma Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Europe Neuroblastoma Treatment Market Size by Country (2021-2026) Table 104. Europe Neuroblastoma Treatment Market Size by Country (2027-2032) Table 105. China Neuroblastoma Treatment Market Size by Type (2021-2026) & (US$ Million) Table 106. China Neuroblastoma Treatment Market Size by Type (2027-2032) & (US$ Million) Table 107. China Neuroblastoma Treatment Market Size by Application (2021-2026) & (US$ Million) Table 108. China Neuroblastoma Treatment Market Size by Application (2027-2032) & (US$ Million) Table 109. Asia Neuroblastoma Treatment Market Size by Type (2021-2026) & (US$ Million) Table 110. Asia Neuroblastoma Treatment Market Size by Type (2027-2032) & (US$ Million) Table 111. Asia Neuroblastoma Treatment Market Size by Application (2021-2026) & (US$ Million) Table 112. Asia Neuroblastoma Treatment Market Size by Application (2027-2032) & (US$ Million) Table 113. Asia Neuroblastoma Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. Asia Neuroblastoma Treatment Market Size by Country (2021-2026) Table 115. Asia Neuroblastoma Treatment Market Size by Country (2027-2032) Table 116. South America, Middle East & Africa Neuroblastoma Treatment Market Size by Type (2021-2026) & (US$ Million) Table 117. South America, Middle East & Africa Neuroblastoma Treatment Market Size by Type (2027-2032) & (US$ Million) Table 118. South America, Middle East & Africa Neuroblastoma Treatment Market Size by Application (2021-2026) & (US$ Million) Table 119. South America, Middle East & Africa Neuroblastoma Treatment Market Size by Application (2027-2032) & (US$ Million) Table 120. South America, Middle East & Africa Neuroblastoma Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. South America, Middle East & Africa Neuroblastoma Treatment Market Size by Country (2021-2026) Table 122. South America, Middle East & Africa Neuroblastoma Treatment Market Size by Country (2027-2032) Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Neuroblastoma Treatment Product Image Figure 2. Global Neuroblastoma Treatment Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Neuroblastoma Treatment Market Share by Type: 2025 VS 2032 Figure 4. Vaccine Therapy Image Figure 5. Oncolytic Virus Therapy Image Figure 6. Chimeric Antigen Receptor T-Cell Immunotherapy Image Figure 7. Combination Chemotherapy Image Figure 8. Monoclonal Antibody Therapy Image Figure 9. Global Neuroblastoma Treatment Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Neuroblastoma Treatment Market Share by Application: 2025 VS 2032 Figure 11. Hospitals Image Figure 12. Clinics Image Figure 13. Others Image Figure 14. Global Neuroblastoma Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 16. Global Neuroblastoma Treatment Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Neuroblastoma Treatment Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Neuroblastoma Treatment Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Neuroblastoma Treatment Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Neuroblastoma Treatment Revenue Market Share by Type (2021-2032) Figure 23. Global Neuroblastoma Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Neuroblastoma Treatment Revenue Market Share by Application (2021-2032) Figure 25. North America Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 26. North America Neuroblastoma Treatment Market Share by Type (2021-2032) Figure 27. North America Neuroblastoma Treatment Market Share by Application (2021-2032) Figure 28. North America Neuroblastoma Treatment Market Share by Country (2021-2032) Figure 29. United States Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 30. Canada Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 32. Europe Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 33. Europe Neuroblastoma Treatment Market Share by Type (2021-2032) Figure 34. Europe Neuroblastoma Treatment Market Share by Application (2021-2032) Figure 35. Europe Neuroblastoma Treatment Market Share by Country (2021-2032) Figure 36. Germany Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 37. France Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 39. Italy Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 40. Russia Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 42. China Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 43. China Neuroblastoma Treatment Market Share by Type (2021-2032) Figure 44. China Neuroblastoma Treatment Market Share by Application (2021-2032) Figure 45. Asia Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 46. Asia Neuroblastoma Treatment Market Share by Type (2021-2032) Figure 47. Asia Neuroblastoma Treatment Market Share by Application (2021-2032) Figure 48. Asia Neuroblastoma Treatment Market Share by Country (2021-2032) Figure 49. Japan Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 53. India Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 54. Australia Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Neuroblastoma Treatment Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Neuroblastoma Treatment Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Neuroblastoma Treatment Market Share by Country (2021-2032) Figure 59. Brazil Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 64. UAE Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 66. Chile Neuroblastoma Treatment Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • Vaccine Therapy
  • Oncolytic Virus Therapy
  • Chimeric Antigen Receptor T-Cell Immunotherapy
  • Combination Chemotherapy
  • Monoclonal Antibody Therapy
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Adaptimmune
  • CureSearch
  • Juno Therapeutics
  • Kite Pharma
  • NANT
  • Seattle Children’s
  • Texas Children’s
  • Fosun Pharmaceutical
  • Jiangsu Hengrui Medicine Co.,Ltd.
  • Novartis
  • Sino Biopharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Neuroblastoma Treatment Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Vaccine Therapy
  5. 1.2.3 Oncolytic Virus Therapy
  6. 1.2.4 Chimeric Antigen Receptor T-Cell Immunotherapy
  7. 1.2.5 Combination Chemotherapy
  8. 1.2.6 Monoclonal Antibody Therapy
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Neuroblastoma Treatment Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Hospitals
  12. 1.3.3 Clinics
  13. 1.3.4 Others
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Neuroblastoma Treatment Growth Trends by Region
  16. 1.5.1 Global Neuroblastoma Treatment Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Neuroblastoma Treatment Market Size by Region (2021-2026)
  18. 1.5.3 Neuroblastoma Treatment Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Neuroblastoma Treatment Market Dynamics
  1. 2.1 Neuroblastoma Treatment Industry Trends
  2. 2.2 Neuroblastoma Treatment Industry Drivers
  3. 2.3 Neuroblastoma Treatment Industry Opportunities and Challenges
  4. 2.4 Neuroblastoma Treatment Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Neuroblastoma Treatment Revenue by Company (2021-2026)
  2. 3.2 Global Neuroblastoma Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Neuroblastoma Treatment Key Company Head office and Area Served
  4. 3.4 Global Neuroblastoma Treatment Company, Product Type & Application
  5. 3.5 Global Neuroblastoma Treatment Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Neuroblastoma Treatment Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Neuroblastoma Treatment Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Neuroblastoma Treatment Tier 1, Tier 2, and Tier 3
4 Neuroblastoma Treatment Market by Type
  1. 4.1 Global Neuroblastoma Treatment Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Neuroblastoma Treatment Market Size by Type (2021-2032)
  3. 4.3 Global Neuroblastoma Treatment Market Size Share by Type (2021-2032)
5 Neuroblastoma Treatment Market by Application
  1. 5.1 Global Neuroblastoma Treatment Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Neuroblastoma Treatment Market Size by Application (2021-2032)
  3. 5.3 Global Neuroblastoma Treatment Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Adaptimmune
  2. 6.1.1 Adaptimmune Company Information
  3. 6.1.2 Adaptimmune Business Overview
  4. 6.1.3 Adaptimmune Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Adaptimmune Neuroblastoma Treatment Product Portfolio
  6. 6.1.5 Adaptimmune Recent Developments
  7. 6.2 CureSearch
  8. 6.2.1 CureSearch Company Information
  9. 6.2.2 CureSearch Business Overview
  10. 6.2.3 CureSearch Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 CureSearch Neuroblastoma Treatment Product Portfolio
  12. 6.2.5 CureSearch Recent Developments
  13. 6.3 Juno Therapeutics
  14. 6.3.1 Juno Therapeutics Company Information
  15. 6.3.2 Juno Therapeutics Business Overview
  16. 6.3.3 Juno Therapeutics Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Juno Therapeutics Neuroblastoma Treatment Product Portfolio
  18. 6.3.5 Juno Therapeutics Recent Developments
  19. 6.4 Kite Pharma
  20. 6.4.1 Kite Pharma Company Information
  21. 6.4.2 Kite Pharma Business Overview
  22. 6.4.3 Kite Pharma Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Kite Pharma Neuroblastoma Treatment Product Portfolio
  24. 6.4.5 Kite Pharma Recent Developments
  25. 6.5 NANT
  26. 6.5.1 NANT Company Information
  27. 6.5.2 NANT Business Overview
  28. 6.5.3 NANT Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 NANT Neuroblastoma Treatment Product Portfolio
  30. 6.5.5 NANT Recent Developments
  31. 6.6 Seattle Children’s
  32. 6.6.1 Seattle Children’s Company Information
  33. 6.6.2 Seattle Children’s Business Overview
  34. 6.6.3 Seattle Children’s Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Seattle Children’s Neuroblastoma Treatment Product Portfolio
  36. 6.6.5 Seattle Children’s Recent Developments
  37. 6.7 Texas Children’s
  38. 6.7.1 Texas Children’s Company Information
  39. 6.7.2 Texas Children’s Business Overview
  40. 6.7.3 Texas Children’s Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Texas Children’s Neuroblastoma Treatment Product Portfolio
  42. 6.7.5 Texas Children’s Recent Developments
  43. 6.8 Fosun Pharmaceutical
  44. 6.8.1 Fosun Pharmaceutical Company Information
  45. 6.8.2 Fosun Pharmaceutical Business Overview
  46. 6.8.3 Fosun Pharmaceutical Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Fosun Pharmaceutical Neuroblastoma Treatment Product Portfolio
  48. 6.8.5 Fosun Pharmaceutical Recent Developments
  49. 6.9 Jiangsu Hengrui Medicine Co.,Ltd.
  50. 6.9.1 Jiangsu Hengrui Medicine Co.,Ltd. Company Information
  51. 6.9.2 Jiangsu Hengrui Medicine Co.,Ltd. Business Overview
  52. 6.9.3 Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Product Portfolio
  54. 6.9.5 Jiangsu Hengrui Medicine Co.,Ltd. Recent Developments
  55. 6.10 Novartis
  56. 6.10.1 Novartis Company Information
  57. 6.10.2 Novartis Business Overview
  58. 6.10.3 Novartis Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Novartis Neuroblastoma Treatment Product Portfolio
  60. 6.10.5 Novartis Recent Developments
  61. 6.11 Sino Biopharmaceutical
  62. 6.11.1 Sino Biopharmaceutical Company Information
  63. 6.11.2 Sino Biopharmaceutical Business Overview
  64. 6.11.3 Sino Biopharmaceutical Neuroblastoma Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Sino Biopharmaceutical Neuroblastoma Treatment Product Portfolio
  66. 6.11.5 Sino Biopharmaceutical Recent Developments
7 North America
  1. 7.1 North America Neuroblastoma Treatment Market Size (2021-2032)
  2. 7.2 North America Neuroblastoma Treatment Market Size by Type
  3. 7.2.1 North America Neuroblastoma Treatment Market Size by Type (2021-2026)
  4. 7.2.2 North America Neuroblastoma Treatment Market Size by Type (2027-2032)
  5. 7.2.3 North America Neuroblastoma Treatment Market Share by Type (2021-2032)
  6. 7.3 North America Neuroblastoma Treatment Market Size by Application
  7. 7.3.1 North America Neuroblastoma Treatment Market Size by Application (2021-2026)
  8. 7.3.2 North America Neuroblastoma Treatment Market Size by Application (2027-2032)
  9. 7.3.3 North America Neuroblastoma Treatment Market Share by Application (2021-2032)
  10. 7.4 North America Neuroblastoma Treatment Market Size by Country
  11. 7.4.1 North America Neuroblastoma Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Neuroblastoma Treatment Market Size by Country (2021-2026)
  13. 7.4.3 North America Neuroblastoma Treatment Market Size by Country (2027-2032)
  14. 7.4.4 North America Neuroblastoma Treatment Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Neuroblastoma Treatment Market Size (2021-2032)
  2. 8.2 Europe Neuroblastoma Treatment Market Size by Type
  3. 8.2.1 Europe Neuroblastoma Treatment Market Size by Type (2021-2026)
  4. 8.2.2 Europe Neuroblastoma Treatment Market Size by Type (2027-2032)
  5. 8.2.3 Europe Neuroblastoma Treatment Market Share by Type (2021-2032)
  6. 8.3 Europe Neuroblastoma Treatment Market Size by Application
  7. 8.3.1 Europe Neuroblastoma Treatment Market Size by Application (2021-2026)
  8. 8.3.2 Europe Neuroblastoma Treatment Market Size by Application (2027-2032)
  9. 8.3.3 Europe Neuroblastoma Treatment Market Share by Application (2021-2032)
  10. 8.4 Europe Neuroblastoma Treatment Market Size by Country
  11. 8.4.1 Europe Neuroblastoma Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Neuroblastoma Treatment Market Size by Country (2021-2026)
  13. 8.4.3 Europe Neuroblastoma Treatment Market Size by Country (2027-2032)
  14. 8.4.4 Europe Neuroblastoma Treatment Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Neuroblastoma Treatment Market Size (2021-2032)
  2. 9.2 China Neuroblastoma Treatment Market Size by Type
  3. 9.2.1 China Neuroblastoma Treatment Market Size by Type (2021-2026)
  4. 9.2.2 China Neuroblastoma Treatment Market Size by Type (2027-2032)
  5. 9.2.3 China Neuroblastoma Treatment Market Share by Type (2021-2032)
  6. 9.3 China Neuroblastoma Treatment Market Size by Application
  7. 9.3.1 China Neuroblastoma Treatment Market Size by Application (2021-2026)
  8. 9.3.2 China Neuroblastoma Treatment Market Size by Application (2027-2032)
  9. 9.3.3 China Neuroblastoma Treatment Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Neuroblastoma Treatment Market Size (2021-2032)
  2. 10.2 Asia Neuroblastoma Treatment Market Size by Type
  3. 10.2.1 Asia Neuroblastoma Treatment Market Size by Type (2021-2026)
  4. 10.2.2 Asia Neuroblastoma Treatment Market Size by Type (2027-2032)
  5. 10.2.3 Asia Neuroblastoma Treatment Market Share by Type (2021-2032)
  6. 10.3 Asia Neuroblastoma Treatment Market Size by Application
  7. 10.3.1 Asia Neuroblastoma Treatment Market Size by Application (2021-2026)
  8. 10.3.2 Asia Neuroblastoma Treatment Market Size by Application (2027-2032)
  9. 10.3.3 Asia Neuroblastoma Treatment Market Share by Application (2021-2032)
  10. 10.4 Asia Neuroblastoma Treatment Market Size by Country
  11. 10.4.1 Asia Neuroblastoma Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Neuroblastoma Treatment Market Size by Country (2021-2026)
  13. 10.4.3 Asia Neuroblastoma Treatment Market Size by Country (2027-2032)
  14. 10.4.4 Asia Neuroblastoma Treatment Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Neuroblastoma Treatment Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Neuroblastoma Treatment Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Neuroblastoma Treatment Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Neuroblastoma Treatment Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Neuroblastoma Treatment Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Neuroblastoma Treatment Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Neuroblastoma Treatment Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Neuroblastoma Treatment Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Neuroblastoma Treatment Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Neuroblastoma Treatment Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Neuroblastoma Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Neuroblastoma Treatment Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Neuroblastoma Treatment Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Neuroblastoma Treatment Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst